Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 3 1

Status

Recruiting 13Active not recruiting 5Withdrawn 2Terminated 2Completed 2Suspended 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Breast Neoplasms 1

Interventions

Paclitaxel 291Gemcitabine 254Carboplatin 253Cisplatin 250Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 180Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Ipilimumab 90Pemetrexed 89fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Completed × decitabine and cedazuridine drug combination × Clear all
NCT03813186 2024-08-02

Effect of Food on Blood Levels of ASTX727

Astex Pharmaceuticals, Inc.

Phase 1 Completed
18 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04134884 2024-03-22

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Indiana University

Phase 1 Completed
34 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡